Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14103622 | 0.90 | ALDH1A1 (0.45) | ALDH1A1GAAHTTNAMPTKDM4E | |
| SCHEMBL4887300 | 0.90 | CFD (0.49) | ALDH1A1GAAHTTKDM4E | |
| SCHEMBL4887422 | 0.89 | NAMPT (0.54) | ALDH1A1NAMPTKDM4E | |
| SCHEMBL4883875 | 0.87 | HDAC1 (0.40) | ALDH1A1HTTNAMPTKDM4E | |
| SCHEMBL4896179 | 0.84 | RAB9A (0.58) | ALDH1A1GAAKDM4E | |
| SCHEMBL4889436 | 0.82 | NPC1 (0.40) | ALDH1A1GAAHTTKDM4E | |
| SCHEMBL4893146 | 0.82 | EPHX2 (0.44) | ALDH1A1HTTNAMPTKDM4E | |
| SCHEMBL4892221 | 0.81 | ALDH1A1 (0.48) | ALDH1A1HTTKDM4E | |
| SCHEMBL4892975 | 0.81 | CYP1A2 (0.50) | ALDH1A1GAAHTTKDM4E | |
| SCHEMBL4889541 | 0.80 | KDM4E (0.42) | ALDH1A1GAAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | ALDH1A1 276/4885GAA 1626/4885HTT 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.